论文部分内容阅读
目的了解妥洛特罗贴剂治疗支气管哮喘的有效性和安全性。方法共有91例轻中度持续哮喘患者入选本研究,妥洛特罗贴剂组46例,每贴2mg,每晚1次,多索茶碱片组45例,0.3g/次,2次/d。治疗4周后观察呼吸流量峰值(PEF)、症状评分、使用速效缓解药物的次数、哮喘控制测试表(ACT)评分及不良反应发生情况。结果治疗4周后,1妥洛特罗贴剂组日间症状评分较治疗前显著下降,差异有统计学意义(P<0.05),且较对照组明显下降,差异有统计学意义(P<0.05);妥洛特罗贴剂夜间症状评分较治疗前显著下降,差异有统计学意义(P<0.05),但较对照组下降不明显;2妥洛特罗贴剂组使用速效缓解药物次数较治疗前显著下降,差异有统计学意义(P<0.05),但较对照组下降不明显;3妥洛特罗贴剂ACT评分较治疗前显著增加,差异有统计学意义(P<0.05),较对照组明显增加,差异有统计学意义(P<0.05);4治疗2周及4周后,妥洛特罗贴剂组晨间及睡前PEF均较治疗前显著增加,差异有统计学意义(P<0.05),且较对照组也明显增加;试验期间妥洛特罗贴剂组未出现不良事件,对照组出1例心悸。结论妥洛特罗贴剂是一种安全、有效的哮喘治疗药物。
Objective To investigate the efficacy and safety of tulobuterol in the treatment of bronchial asthma. Methods A total of 91 patients with mild-to-moderate persistent asthma were enrolled in this study. Forty-six patients were treated with tulobuterol patch, 2 mg / tablet, once per night, and 45 cases were treated with doxofylline, 0.3g / d. After 4 weeks of treatment, the peak respiratory flow (PEF), symptom score, the number of drugs used to relieve pain, the asthma control test (ACT) score and the incidence of adverse reactions were observed. Results After 4 weeks of treatment, the daytime symptom score of 1-tulobuterol patch group was significantly lower than that before treatment (P <0.05), and was significantly lower than that of the control group (P < 0.05). The nighttime symptom score of tulobuterol patch decreased significantly compared with that before treatment (P <0.05), but no significant difference compared with the control group. (2) (P <0.05), but there was no significant difference compared with the control group. (3) The ACT score of tulobuterol patch significantly increased compared with that before treatment (P <0.05), and the difference was statistically significant (P <0.05). After 2 weeks and 4 weeks of treatment, the values of PEF in morning and evening before treatment were significantly increased in the tulobuterol patch group compared with those before treatment, with statistical difference (P <0.05), and also significantly increased compared with the control group. There was no adverse events in the tulobuterol patch group during the trial, and 1 case of palpitations in the control group. Conclusion The tulobuterol patch is a safe and effective asthma medication.